Equities research analysts expect EverQuote, Inc. (NASDAQ:EVER) to report $101.24 million in sales for the current quarter, Zacks reports. Four analysts have provided estimates for EverQuote’s earnings. The lowest sales estimate is $100.70 million and the highest is $101.80 million. EverQuote posted sales of $81.36 million during the same quarter last year, which suggests a positive year-over-year growth rate of 24.4%. The business is scheduled to issue its next earnings results on Monday, May 3rd.
According to Zacks, analysts expect that EverQuote will report full-year sales of $435.51 million for the current financial year, with estimates ranging from $434.49 million to $437.78 million. For the next year, analysts expect that the company will report sales of $521.29 million, with estimates ranging from $507.47 million to $546.50 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow EverQuote.
EverQuote (NASDAQ:EVER) last released its quarterly earnings results on Sunday, February 21st. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. EverQuote had a negative net margin of 2.59% and a negative return on equity of 14.19%. The company had revenue of $97.30 million during the quarter, compared to the consensus estimate of $91.79 million. During the same period in the previous year, the business earned ($0.04) earnings per share. The firm’s quarterly revenue was up 31.8% on a year-over-year basis.
A number of research firms have recently weighed in on EVER. JPMorgan Chase & Co. dropped their price target on shares of EverQuote from $54.00 to $48.00 and set an “overweight” rating for the company in a research report on Wednesday, December 16th. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of EverQuote from a “sell” rating to a “hold” rating and set a $47.00 price objective for the company in a research report on Tuesday, February 23rd. Oppenheimer restated a “buy” rating and set a $70.00 price objective (up from $55.00) on shares of EverQuote in a research report on Tuesday, February 23rd. Raymond James boosted their price objective on shares of EverQuote from $51.00 to $58.00 and gave the company an “outperform” rating in a research report on Monday, March 1st. Finally, Needham & Company LLC restated a “buy” rating and set a $65.00 price objective on shares of EverQuote in a research report on Tuesday, February 23rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. EverQuote presently has a consensus rating of “Buy” and an average price target of $56.13.
In other EverQuote news, Director David B. Blundin sold 24,241 shares of the business’s stock in a transaction on Monday, March 1st. The shares were sold at an average price of $50.13, for a total transaction of $1,215,201.33. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, General Counsel David W. Mason sold 1,799 shares of the business’s stock in a transaction on Wednesday, March 31st. The stock was sold at an average price of $35.29, for a total transaction of $63,486.71. Following the sale, the general counsel now directly owns 117,945 shares in the company, valued at approximately $4,162,279.05. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 92,396 shares of company stock worth $4,383,873. Insiders own 45.70% of the company’s stock.
Several institutional investors have recently modified their holdings of the stock. UBS Asset Management Americas Inc. grew its stake in shares of EverQuote by 32.2% in the fourth quarter. UBS Asset Management Americas Inc. now owns 7,800 shares of the company’s stock worth $291,000 after purchasing an additional 1,900 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its stake in shares of EverQuote by 10,511.1% in the fourth quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 191,000 shares of the company’s stock worth $7,134,000 after purchasing an additional 189,200 shares during the last quarter. Hsbc Holdings PLC grew its stake in shares of EverQuote by 11.5% in the fourth quarter. Hsbc Holdings PLC now owns 7,101 shares of the company’s stock worth $260,000 after purchasing an additional 733 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of EverQuote by 129.1% in the fourth quarter. JPMorgan Chase & Co. now owns 45,397 shares of the company’s stock worth $1,695,000 after purchasing an additional 25,581 shares during the last quarter. Finally, Verition Fund Management LLC bought a new stake in shares of EverQuote in the fourth quarter worth $1,974,000. 60.85% of the stock is currently owned by institutional investors.
Shares of NASDAQ EVER traded up $0.40 during midday trading on Friday, reaching $36.84. The company’s stock had a trading volume of 3,875 shares, compared to its average volume of 290,294. EverQuote has a fifty-two week low of $28.08 and a fifty-two week high of $63.44. The business’s 50 day moving average price is $41.52 and its two-hundred day moving average price is $40.03. The company has a market cap of $1.05 billion, a P/E ratio of -119.58 and a beta of 1.58.
EverQuote Company Profile
EverQuote, Inc operates an online marketplace for insurance shopping in the United States. The company's online marketplace offers consumers shopping for auto, home and renters, life, health, and commercial insurance. It serves carriers and agents, as well as indirect distributors. The company was formerly known as AdHarmonics, Inc, and changed its name to EverQuote, Inc in November 2014.
Featured Story: What is an overbought condition?
Get a free copy of the Zacks research report on EverQuote (EVER)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for EverQuote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EverQuote and related companies with MarketBeat.com's FREE daily email newsletter.